| Autor: |
Antila, Saila, Kivikko, Matti, Lehtonen, Lasse, Eha, Jaan, Heikkila, Aira, Pohjanjousi, Pasi, Pentikainen, Pertti J. |
| Předmět: |
|
| Zdroj: |
British Journal of Clinical Pharmacology; Apr2004, Vol. 57 Issue 4, p412-415, 4p |
| Abstrakt: |
The purpose of the study was to characterize the pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in patients with congestive heart failure. Levosimendan was administered as a continuous intravenous infusion for 7 days. Twelve subjects received the drug at an infusion rate of 0.05 µg kg−1 min−1 and 12 at a rate 0.1 µg kg−1 min−1. Steady state concentrations of levosimendan were achieved within 4 h. Peak concentrations of the metabolites occurred after termination of the infusion. The mean (± SD) half-life of the active metabolite OR-1896 was 81 ± 37 h after the lower dose and 81 ± 28 h after the higher dose ( P = 0.992, 95% confidence interval on the difference −27.5, 27.7). The metabolites of levosimendan, OR-1855 and OR-1896, were formed and eliminated slowly, their peak concentrations occurring after termination of the 7-day infusion of the drug. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text